Sylentis Sau
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
5
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 16, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,807,650 | Methods and Compositions for the Treatment of Intestinal Conditions In force · High confidence | In force | High confidence | |
| US 8,354,385 | Modulation of TRPV expression levels In force · From the USPTO record | In force | From the USPTO record | |
| US 8,871,729 | Treatment of CNS conditions In force · From the USPTO record | In force | From the USPTO record | |
| US 8,188,057 | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 8,703,731 | Sphingosine-bound siRNA In force · From the USPTO record | In force | From the USPTO record | |
| US 9,018,183 | Sirna and Their Use in Methods and Compositions for the Treatment And/Or Prevention of Eye Conditions In force · High confidence | In force | High confidence | |
| US 10,011,832 | SiRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions In force · From the USPTO record | In force | From the USPTO record | |
| US 9,808,479 | SiRNA and their use in methods and compositions for the treatment and / or prevention of eye conditions In force · From the USPTO record | In force | From the USPTO record | |
| US 9,951,338 | siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene In force · From the USPTO record | In force | From the USPTO record | |
| US 10,017,766 | SiRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 13: 12 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 no status recorded